• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by LENSAR Inc.

    3/25/25 9:52:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    LENSAR, Inc.

    (Name of Issuer)


    Common Stock, $0.01 par value

    (Title of Class of Securities)


    52634L108

    (CUSIP Number)


    Todd B. Hammer
    North Run Capital, LP , 867 Boylston Street, 5th Floor #1361
    Boston, MA, 02116
    0000000000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/23/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    52634L108


    1 Name of reporting person

    North Run Capital, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,100,592.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,100,592.00
    11Aggregate amount beneficially owned by each reporting person

    1,100,592.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.3 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    52634L108


    1 Name of reporting person

    North Run Advisors, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,100,592.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,100,592.00
    11Aggregate amount beneficially owned by each reporting person

    1,100,592.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.3 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    52634L108


    1 Name of reporting person

    NR-GRI Partners, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    12,307,692.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    12,307,692.00
    11Aggregate amount beneficially owned by each reporting person

    12,307,692.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    51.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    52634L108


    1 Name of reporting person

    NR-GRI Partners GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    12,307,692.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    12,307,692.00
    11Aggregate amount beneficially owned by each reporting person

    12,307,692.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    51.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    52634L108


    1 Name of reporting person

    ELLIS THOMAS B
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    127,654.00
    8Shared Voting Power

    13,408,284.00
    9Sole Dispositive Power

    127,654.00
    10Shared Dispositive Power

    13,408,284.00
    11Aggregate amount beneficially owned by each reporting person

    13,535,938.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    55.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    52634L108


    1 Name of reporting person

    HAMMER TODD B
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    127,654.00
    8Shared Voting Power

    13,408,284.00
    9Sole Dispositive Power

    127,654.00
    10Shared Dispositive Power

    13,408,284.00
    11Aggregate amount beneficially owned by each reporting person

    13,535,938.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    55.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.01 par value
    (b)Name of Issuer:

    LENSAR, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    2800 DISCOVERY DRIVE SUITE 100, ORLANDO, FLORIDA , 32826.
    Item 1 Comment:
    This Amendment No. 1 ("Amendment No. 1" amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission on May 19, 2023 (the "Original Schedule 13D" and the Original Schedule 13D as amended, the "Schedule 13D"). This Amendment No. 1 amends and supplements Items 4, 5 and 6 as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D.
    Item 4.Purpose of Transaction
     
    Item 4 is hereby amended and supplemented to add the following at the end thereof: On March 23, 2025, concurrent with the execution of an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Alcon Research, LLC ("Parent") and its wholly owned subsidiary VMI Option Merger Sub, Inc. ("Merger Sub"), the Reporting Persons entered into a Voting Agreement with Parent (the "Voting Agreement") providing that, among other things, subject to the terms and conditions set forth therein, such signatories will support the merger of Merger Sub with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger") and the transactions contemplated by the Merger Agreement, including by voting their voting securities to adopt the Merger Agreement. The Voting Agreement is subject to termination rights, limitations, and cut-backs, in each case as further described in the Voting Agreement. The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Voting Agreement, which is referenced as Exhibit 99.6 hereto and is incorporated herein by reference.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5 is hereby amended and restated in its entirety to read as follows: The aggregate percentage of shares reported owned by each person named herein is based upon 11,789,492 shares of common stock ("Shares") outstanding as of January 31, 2025, which is the total number of Shares outstanding as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 27, 2025, and assumes the exercise of the reported stock options and Warrants and/or the conversion of the Series A Preferred. As of the date hereof, North Run Capital, LP ("North Run LP") directly beneficially owns 1,100,592 Shares, constituting approximately 9.3% of the Shares outstanding. North Run Advisors, LLC ("North Run Advisors"), as the general partner of North Run LP, may be deemed to beneficially own the 1,100,592 Shares beneficially owned by North Run LP, constituting approximately 9.3% of the Shares outstanding. As of the date hereof, NR-GRI Partners, LP ("NR-GRI LP") directly beneficially owns 12,307,692 Shares, which are issuable upon exercise of the Warrants and/or conversion of the Series A Preferred, constituting 51.1% of the Shares outstanding. NR-GRI Partners GP, LLC ("NR-GRI GP"), as the general partner of NR-GRI LP, may be deemed to beneficially own the 12,307,692 Shares beneficially owned by NR-GRI LP that are issuable upon exercise of the Warrants and/or conversion of the Series A Preferred, constituting approximately 51.1% of the Shares outstanding.. Each of Mr. Hammer and Mr. Ellis, as the sole members of NR-GRI GP and North Run Advisors, may be deemed to beneficially own (i) the 1,100,592 Shares beneficially owned by North Run LP, (ii) the 12,307,692 Shares beneficially owned by NR-GRI LP that are issuable upon exercise of the Warrants and/or conversion of the Series A Preferred, (iii) 9,288 Shares held directly by each of Mr. Hammer and Mr. Ellis as a result of restricted stock units that have vested, (iv) 22,000 Shares that may become issuable pursuant to restricted stock units held directly by each of Mr. Hammer and Mr. Ellis that will vest within 60 days of March 25, 2025, and (v) 96,366 Shares that may become issuable pursuant to the exercise of stock options held directly by each of Mr. Hammer and Mr. Ellis that have vested or will vest within 60 days of March 25, 2025, in each case constituting approximately 55.9% of the Shares outstanding. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.
    (b)
    Each of North Run Advisors and Messrs. Hammer and Ellis may be deemed to share the power to vote and dispose of the Shares owned by North Run LP. Each of NR-GRI GP and Messrs. Hammer and Ellis may be deemed to share the power to vote and dispose of the Shares owned by NR-GRI LP.
    (c)
    Except as otherwise set forth herein, there have been no transactions in securities of the Issuer by the Reporting Persons during the past 60 days.
    (d)
    No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 is hereby amended and supplemented to add the following at the end thereof: The disclosure with respect to the Merger and the Voting Agreement set forth in Item 4 above, including the description of the Voting Agreement, is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 is hereby amended and supplemented to add the following at the end thereof: 99.6 - Form of Voting Agreement (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K filed by the Issuer, dated March 24, 2025).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    North Run Capital, LP
     
    Signature:/s/Todd B. Hammer
    Name/Title:Todd B. Hammer, Member of North Run Advisors, LLC, its General Partner
    Date:03/25/2025
     
    North Run Advisors, LLC
     
    Signature:/s/Todd B. Hammer
    Name/Title:Todd B. Hammer, Member
    Date:03/25/2025
     
    NR-GRI Partners, LP
     
    Signature:/s/Todd B. Hammer
    Name/Title:Todd B. Hammer, Member of NR-GRI Partners GP, LLC, its General Partner
    Date:03/25/2025
     
    NR-GRI Partners GP, LP
     
    Signature:/s/Todd B. Hammer
    Name/Title:Todd B. Hammer, Member
    Date:03/25/2025
     
    ELLIS THOMAS B
     
    Signature:/s/ Thomas B. Ellis
    Name/Title:Thomas B. Ellis
    Date:03/25/2025
     
    HAMMER TODD B
     
    Signature:/s/Todd B. Hammer
    Name/Title:Todd B. Hammer
    Date:03/25/2025
    Get the next $LNSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,826 shares, decreasing direct ownership by 1% to 171,535 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:07 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:11 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,262 shares, decreasing direct ownership by 0.63% to 359,461 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:06 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the

    9/2/25 4:01:44 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    SEC Filings

    View All

    LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LENSAR, Inc. (0001320350) (Filer)

    12/19/25 4:01:27 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by LENSAR Inc.

    SCHEDULE 13G - LENSAR, Inc. (0001320350) (Subject)

    11/13/25 12:03:17 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by LENSAR Inc.

    10-Q - LENSAR, Inc. (0001320350) (Filer)

    11/6/25 4:01:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    3/2/21 8:10:50 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    2/24/21 6:12:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports First Quarter 2025 Results and Provides Business Update

             14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

    5/8/25 7:00:42 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

    2/27/25 7:00:11 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care